Salix Pharmaceuticals (SLXP)

Add to Watchlists
Create an Alert
101.06 +0.40  +0.40% NASDAQ Apr 17, 8:00PM BATS Real time Currency in USD
View Full Chart
SLXP Price Chart
View All Events

SLXP Events

Date Type Description
Feb 27 Misc Q4 2013 Salix Pharmaceuticals Conference Call
Feb 27 Earnings Q4 2013 Salix Pharmaceuticals Earnings Results. Estimate: 0.64.
Jan 02 Misc Salix Pharmaceuticals Completes Acquisition of Santarus
Nov 07 Misc Salix Pharmaceuticals to Acquire Santarus
Nov 07 Misc Salix Pharmaceuticals Announces 3Q2013 Financial Results Conference Call and Webcast
Nov 07 Earnings Q3 2013 Financial Results. Estimate: 0.92.
Aug 08 Misc Salix Pharmaceuticals Announces 2Q2013 Financial Results Conference Call and Webcast
Aug 08 Earnings Q2 2013 Financial Results. Estimate: 0.82.
Jun 13 Misc AGM Event for Salix Pharmaceuticals Ltd
May 30 Misc Salix Pharmaceuticals Acquires Worldwide Rights to Olon’s Intellectual Property Relating to Amorphous Rifaximin
View All Performance Charts

SLXP Total Returns Comparison

This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Salix Pharmaceuticals is up 107.5% over the last year vs S&P 500 Total Return up 23.54%, Questcor Pharmaceuticals up 178.4%, and Shire up 67.17%.

Get Quote for

PDF Report for SLXP

Download Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.

Download SLXP Pro Report PDF

Portfolio Strategies Featuring SLXP

Did Salix Pharmaceuticals make it into our Portfolio Strategies?
Start your YCharts membership now to find out.

SLXP Profile

  • Sector: Healthcare
  • Industry: Drug Manufacturers - Specialty & Generic
  • Headquarters Country: United States
  • Headquarters State/Province: North Carolina
  • Incorporation Country: United States
  • Incorporation State/Province: Delaware
  • Est. Current Fiscal Quarter End: June 30, 2014
  • Est. Current Fiscal Year End: December 31, 2014
  • Last Fiscal Quarter End: N/A
  • Last Fiscal Year End: N/A
  • NAICS: Pharmaceutical Preparation Manufacturing
  • NAICS Code: 325412
  • NAICS Industry: Pharmaceutical and Medicine Manufacturing
  • NAICS Industry Code: 3254
  • NAICS Sector: Manufacturing
  • NAICS Sector Code: 32

Salix Pharmaceuticals Ltd. develops and markets prescription pharmaceutical products for the prevention and treatment of gastrointestinal diseases. Salix also markets OSMOPREP Tablets, VISICOL Tablets, APRISO extended-release capsules, METOZOLV, RELISTOR Subcutaneous Injection, PEPCID for Oral Suspension, Oral Suspension DIURIL, AZASAN Tablets, USP, ANUSOL-HC, ANUSOL-HC Suppository, PROCTOCORT Cream and PROCTOCORT Suppository. Crofelemer, budesonide foam, RELISTOR, Lumacan and rifaximin for additional indications are under development. It was founded by Randy W. Hamilton and Lorin K. Johnson in 1989 and is headquartered in Raleigh, North Carolina.

Recent Quotes

Symbol Price Chg Chg % Market Cap
SLXP 101.06 +0.40 +0.40% 6.401B
Create Watchlist from Quotes

Already registered? Click here to sign in.

Access watchlists and custom data alerts.
Start your free account.

Get Started Now

Upgrade to {{}}. Start Your YCharts Membership. Start your {{}} Membership


{{ ? "Upgrade Now" : "Get Started Now"}}

Already a YCharts Member? Already a {{}} Member? Sign in here.